Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells

Objective: To evaluate the performance of the T-SPOT.COVID test for identifying SARS-CoV-2-responsive T-cells in participants with SARS-CoV-2 infection. Methods: The T-SPOT.COVID test uses ELISpot interferon-gamma release assay (IGRA) methodology to measure T cell responses to SARS-CoV-2 spike S1 an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Margaret Kruse, Chris Dark, Megan Aspden, Daniel Cochrane, Rick Competiello, Maya Peltz, Luis Torres, Peter Wrighton-Smith, Magdalena Dudek
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	T-SPOT.COVID COVID-19 SARS-CoV-2 interferon-gamma release assay IGRA serology Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/521b02e525c34976bb57a97f3a3bb505
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:521b02e525c34976bb57a97f3a3bb505
record_format	dspace
spelling	oai:doaj.org-article:521b02e525c34976bb57a97f3a3bb5052021-11-06T04:22:49ZPerformance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells1201-971210.1016/j.ijid.2021.09.073https://doaj.org/article/521b02e525c34976bb57a97f3a3bb5052021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007785https://doaj.org/toc/1201-9712Objective: To evaluate the performance of the T-SPOT.COVID test for identifying SARS-CoV-2-responsive T-cells in participants with SARS-CoV-2 infection. Methods: The T-SPOT.COVID test uses ELISpot interferon-gamma release assay (IGRA) methodology to measure T cell responses to SARS-CoV-2 spike S1 and nucleocapsid peptides. T-SPOT.COVID and anti-N immunoglobulin (Ig) G serology tests were performed on blood from 186 patients with nucleic acid amplification test (NAAT)-confirmed-SARS-CoV-2 infection and 100 control group participants. Results: In the 2–8 weeks after NAAT-diagnosed SARS-CoV-2 infection, the T-SPOT.COVID test detected 98.4% (63 of 64) of infected participants, while anti-N IgG serology detected 82.8%. In the first 2 weeks after diagnosis, during adaptive immune response activation, there were less reactive T-SPOT.COVID responses (75.7%, 28 of 37 infected participants) and many less seropositive responses (32.4%). Response numbers tapered after 8 weeks; however, T-SPOT.COVID test continued to detect most participants with confirmed infection (83.6%, 56 of 67) and continued to out-perform serology (52.2%). T-SPOT.COVID response due to cross-reactive T cells was ruled out by demonstrating that, of 44 control group participants with T cells responsive to 4 human common cold coronavirus peptides, only 1 was T-SPOT.COVID reactive. Conclusion: The T-SPOT.COVID test performed well in detecting SARS-CoV-2-sensitized T-cells over many months.Margaret KruseChris DarkMegan AspdenDaniel CochraneRick CompetielloMaya PeltzLuis TorresPeter Wrighton-SmithMagdalena DudekElsevierarticleT-SPOT.COVIDCOVID-19SARS-CoV-2interferon-gamma release assayIGRAserologyInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 113, Iss , Pp 155-161 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	T-SPOT.COVID COVID-19 SARS-CoV-2 interferon-gamma release assay IGRA serology Infectious and parasitic diseases RC109-216
spellingShingle	T-SPOT.COVID COVID-19 SARS-CoV-2 interferon-gamma release assay IGRA serology Infectious and parasitic diseases RC109-216 Margaret Kruse Chris Dark Megan Aspden Daniel Cochrane Rick Competiello Maya Peltz Luis Torres Peter Wrighton-Smith Magdalena Dudek Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
description	Objective: To evaluate the performance of the T-SPOT.COVID test for identifying SARS-CoV-2-responsive T-cells in participants with SARS-CoV-2 infection. Methods: The T-SPOT.COVID test uses ELISpot interferon-gamma release assay (IGRA) methodology to measure T cell responses to SARS-CoV-2 spike S1 and nucleocapsid peptides. T-SPOT.COVID and anti-N immunoglobulin (Ig) G serology tests were performed on blood from 186 patients with nucleic acid amplification test (NAAT)-confirmed-SARS-CoV-2 infection and 100 control group participants. Results: In the 2–8 weeks after NAAT-diagnosed SARS-CoV-2 infection, the T-SPOT.COVID test detected 98.4% (63 of 64) of infected participants, while anti-N IgG serology detected 82.8%. In the first 2 weeks after diagnosis, during adaptive immune response activation, there were less reactive T-SPOT.COVID responses (75.7%, 28 of 37 infected participants) and many less seropositive responses (32.4%). Response numbers tapered after 8 weeks; however, T-SPOT.COVID test continued to detect most participants with confirmed infection (83.6%, 56 of 67) and continued to out-perform serology (52.2%). T-SPOT.COVID response due to cross-reactive T cells was ruled out by demonstrating that, of 44 control group participants with T cells responsive to 4 human common cold coronavirus peptides, only 1 was T-SPOT.COVID reactive. Conclusion: The T-SPOT.COVID test performed well in detecting SARS-CoV-2-sensitized T-cells over many months.
format	article
author	Margaret Kruse Chris Dark Megan Aspden Daniel Cochrane Rick Competiello Maya Peltz Luis Torres Peter Wrighton-Smith Magdalena Dudek
author_facet	Margaret Kruse Chris Dark Megan Aspden Daniel Cochrane Rick Competiello Maya Peltz Luis Torres Peter Wrighton-Smith Magdalena Dudek
author_sort	Margaret Kruse
title	Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
title_short	Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
title_full	Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
title_fullStr	Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
title_full_unstemmed	Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
title_sort	performance of the t-spotⓡ.covid test for detecting sars-cov-2-responsive t cells
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/521b02e525c34976bb57a97f3a3bb505
work_keys_str_mv	AT margaretkruse performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT chrisdark performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT meganaspden performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT danielcochrane performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT rickcompetiello performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT mayapeltz performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT luistorres performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT peterwrightonsmith performanceofthetspotcovidtestfordetectingsarscov2responsivetcells AT magdalenadudek performanceofthetspotcovidtestfordetectingsarscov2responsivetcells
_version_	1718443916009668608

Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells

Ejemplares similares